GH Research (GHRS) vs Structure Therapeutics (GPCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
GH Research (GHRS) has outperformed Structure Therapeutics (GPCR) over the past year, gaining 25.1% versus a loss of 53.0%. GH Research is the larger company by market cap ($1.20 billion vs $1.15 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GHRS | GPCR |
|---|---|---|
| Share price | $17.53 | $16.13 |
| Market cap | $1.20B | $1.15B |
| 1-day change | -5.55% | -5.78% |
| YTD return | +38.03% | -76.81% |
| 1-year return | +25.08% | -53.00% |
| 5-year return | -21.00% | — |
| EPS (TTM) | $-0.94 | $-3.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-48.26M | $-141.20M |
| 52-week high | $31.44 | $94.90 |
| 52-week low | $12.04 | $16.06 |
| Distance from 52-week high | -44.24% | -83.00% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +144.67% | +550.09% |
| Average volume | 294.69K | 1.18M |
| Shares outstanding | 68.68M | 71.59M |
| Employees | 73 | 281 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GHRS has outperformed GPCR by 78.1 percentage points over the past year.
About GH Research
GHRS stock →GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression.
Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees
About Structure Therapeutics
GPCR stock →Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 281 employees
GHRS vs GPCR FAQ
Which is bigger, GH Research or Structure Therapeutics?
GH Research (GHRS) is larger, with a market capitalization of $1.20B compared with $1.15B for Structure Therapeutics (GPCR).
Which stock has performed better over the past year, GHRS or GPCR?
GHRS returned +25.08% over the past 12 months, compared with -53.00% for GPCR (price return, excluding dividends). Past performance does not predict future results.
Are GH Research and Structure Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.